These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1144 related articles for article (PubMed ID: 21772129)
1. Results of two bi-institutional prospective studies using intraperitoneal oxaliplatin with or without irinotecan during HIPEC after cytoreductive surgery for colorectal carcinomatosis. Quenet F; Goéré D; Mehta SS; Roca L; Dumont F; Hessissen M; Saint-Aubert B; Elias D Ann Surg; 2011 Aug; 254(2):294-301. PubMed ID: 21772129 [TBL] [Abstract][Full Text] [Related]
2. The treatment of peritoneal carcinomatosis of colorectal cancer with complete cytoreductive surgery and hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) with oxaliplatin: a Belgian multicentre prospective phase II clinical study. Hompes D; D'Hoore A; Van Cutsem E; Fieuws S; Ceelen W; Peeters M; Van der Speeten K; Bertrand C; Legendre H; Kerger J Ann Surg Oncol; 2012 Jul; 19(7):2186-94. PubMed ID: 22395983 [TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant chemotherapy with bevacizumab may improve outcome after cytoreduction and hyperthermic intraperitoneal chemoperfusion (HIPEC) for colorectal carcinomatosis. Ceelen W; Van Nieuwenhove Y; Putte DV; Pattyn P Ann Surg Oncol; 2014 Sep; 21(9):3023-8. PubMed ID: 24756812 [TBL] [Abstract][Full Text] [Related]
4. Oxaliplatin-based versus irinotecan-based hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with peritoneal metastasis from appendiceal and colorectal cancer: a retrospective analysis. Glockzin G; Gerken M; Lang SA; Klinkhammer-Schalke M; Piso P; Schlitt HJ BMC Cancer; 2014 Nov; 14():807. PubMed ID: 25369730 [TBL] [Abstract][Full Text] [Related]
5. Hyperthermic intraperitoneal chemotherapy + early postoperative intraperitoneal chemotherapy versus hyperthermic intraperitoneal chemotherapy alone: assessment of survival outcomes for colorectal and high-grade appendiceal peritoneal carcinomatosis. Lam JY; McConnell YJ; Rivard JD; Temple WJ; Mack LA Am J Surg; 2015 Sep; 210(3):424-30. PubMed ID: 26051744 [TBL] [Abstract][Full Text] [Related]
6. Treatment-related morbidity and toxicity of CRS and oxaliplatin-based HIPEC compared to a mitomycin and doxorubicin-based HIPEC protocol in patients with peritoneal carcinomatosis: a matched-pair analysis. Glockzin G; von Breitenbuch P; Schlitt HJ; Piso P J Surg Oncol; 2013 May; 107(6):574-8. PubMed ID: 22833286 [TBL] [Abstract][Full Text] [Related]
7. Prospective randomized trial evaluating mandatory second look surgery with HIPEC and CRS vs. standard of care in patients at high risk of developing colorectal peritoneal metastases. Ripley RT; Davis JL; Kemp CD; Steinberg SM; Toomey MA; Avital I Trials; 2010 May; 11():62. PubMed ID: 20500867 [TBL] [Abstract][Full Text] [Related]
8. Predictors of progression in high-grade appendiceal or colorectal peritoneal carcinomatosis after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Baumgartner JM; Tobin L; Heavey SF; Kelly KJ; Roeland EJ; Lowy AM Ann Surg Oncol; 2015 May; 22(5):1716-21. PubMed ID: 25145504 [TBL] [Abstract][Full Text] [Related]
9. Survival prognostic factors in patients with colorectal peritoneal carcinomatosis treated with cytoreductive surgery and intraoperative hyperthermic intraperitoneal chemotherapy: a single institution experience. Nikolic S; Dzodic R; Zegarac M; Djurisic I; Gavrilovic D; Vojinovic V; Kocic M; Santrac N; Radlovic P; Radosavljevic D; Pupic G; Martinovic A J BUON; 2014; 19(1):66-74. PubMed ID: 24659645 [TBL] [Abstract][Full Text] [Related]
10. Peritoneal carcinomatosis index predicts survival in colorectal patients undergoing HIPEC using oxaliplatin: a retrospective single-arm cohort study. Burnett A; Lecompte MA; Trabulsi N; Dubé P; Gervais MK; Trilling B; Cloutier AS; Sideris L World J Surg Oncol; 2019 May; 17(1):83. PubMed ID: 31092250 [TBL] [Abstract][Full Text] [Related]
11. Impact of aggressive histology and location of primary tumor on the efficacy of surgical therapy for peritoneal carcinomatosis of colorectal origin. Winer J; Zenati M; Ramalingam L; Jones H; Zureikat A; Holtzman M; Lee K; Ahrendt S; Pingpank J; Zeh HJ; Bartlett DL; Choudry HA Ann Surg Oncol; 2014 May; 21(5):1456-62. PubMed ID: 24201745 [TBL] [Abstract][Full Text] [Related]
12. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy with lobaplatin and docetaxel improves survival for patients with peritoneal carcinomatosis from abdominal and pelvic malignancies. Wu HT; Yang XJ; Huang CQ; Sun JH; Ji ZH; Peng KW; Zhang Q; Li Y World J Surg Oncol; 2016 Sep; 14(1):246. PubMed ID: 27633880 [TBL] [Abstract][Full Text] [Related]
13. The American Society of Peritoneal Surface Malignancies evaluation of HIPEC with Mitomycin C versus Oxaliplatin in 539 patients with colon cancer undergoing a complete cytoreductive surgery. Prada-Villaverde A; Esquivel J; Lowy AM; Markman M; Chua T; Pelz J; Baratti D; Baumgartner JM; Berri R; Bretcha-Boix P; Deraco M; Flores-Ayala G; Glehen O; Gomez-Portilla A; González-Moreno S; Goodman M; Halkia E; Kusamura S; Moller M; Passot G; Pocard M; Salti G; Sardi A; Senthil M; Spiliotis J; Torres-Melero J; Turaga K; Trout R J Surg Oncol; 2014 Dec; 110(7):779-85. PubMed ID: 25088304 [TBL] [Abstract][Full Text] [Related]
14. Predictive and prognostic survival factors in peritoneal carcinomatosis from appendiceal cancer after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. Jimenez W; Sardi A; Nieroda C; Sittig M; Milovanov V; Nunez M; Aydin N; Gushchin V Ann Surg Oncol; 2014 Dec; 21(13):4218-25. PubMed ID: 24986239 [TBL] [Abstract][Full Text] [Related]
15. Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. Elias D; Lefevre JH; Chevalier J; Brouquet A; Marchal F; Classe JM; Ferron G; Guilloit JM; Meeus P; Goéré D; Bonastre J J Clin Oncol; 2009 Feb; 27(5):681-5. PubMed ID: 19103728 [TBL] [Abstract][Full Text] [Related]
16. Treatment of ovarian metastases of colorectal and appendiceal carcinoma in the era of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Kuijpers AM; Mehta AM; Aalbers AG; van Driel WJ; Boot H; Verwaal VJ Eur J Surg Oncol; 2014 Aug; 40(8):937-42. PubMed ID: 24630923 [TBL] [Abstract][Full Text] [Related]
17. HIPEC + EPIC versus HIPEC-alone: differences in major complications following cytoreduction surgery for peritoneal malignancy. McConnell YJ; Mack LA; Francis WP; Ho T; Temple WJ J Surg Oncol; 2013 May; 107(6):591-6. PubMed ID: 23129533 [TBL] [Abstract][Full Text] [Related]
18. Safety of intraperitoneal Mitomycin C versus intraperitoneal oxaliplatin in patients with peritoneal carcinomatosis of colorectal cancer undergoing cytoreductive surgery and HIPEC. van Eden WJ; Kok NFM; Woensdregt K; Huitema ADR; Boot H; Aalbers AGJ Eur J Surg Oncol; 2018 Feb; 44(2):220-227. PubMed ID: 29258720 [TBL] [Abstract][Full Text] [Related]
19. Cytoreductive Surgery Combined with Hyperthermic Intraperitoneal Chemotherapy with Oxaliplatin Increases the Risk of Postoperative Hemorrhagic Complications: Analysis of Predictive Factors. Charrier T; Passot G; Peron J; Maurice C; Gocevska S; Quénet F; Eveno C; Pocard M; Goere D; Elias D; Ortega-Deballon P; Vaudoyer D; Cotte E; Glehen O Ann Surg Oncol; 2016 Jul; 23(7):2315-22. PubMed ID: 26920385 [TBL] [Abstract][Full Text] [Related]
20. The use of Oxaliplatin or Mitomycin C in HIPEC treatment for peritoneal carcinomatosis from colorectal cancer: a comparative study. Hompes D; D'Hoore A; Wolthuis A; Fieuws S; Mirck B; Bruin S; Verwaal V J Surg Oncol; 2014 May; 109(6):527-32. PubMed ID: 24375059 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]